Related Experiment Video
Updated: Nov 19, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment
Jennifer E Stark1, Jennifer L Cole1
1Department of Pharmacy, Veterans Health Care System of the Ozarks, Fayetteville, AR, USA.
What Is Known And Objective:
Drug-drug interactions can involve inhibition or induction of cell membrane transporters. Deinduction occurs after an inducing agent is stopped.
Case Summary:
This case describes suspected P-glycoprotein (P-gp) deinduction by carbamazepine resulting in a slow viral response during treatment of chronic hepatitis C virus (HCV) infection. Evidence of deinduction occurred beyond clearance of carbamazepine and resulted in extension of HCV treatment.
What Is New:
The understanding of the role P-gp transport plays in drug elimination is relatively new and evidence of P-gp deinduction is variable.
Conclusion:
Clinicians should consider deinduction when starting and stopping medications involving strong inducers of P-gp transport proteins.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Pharmacokinetics: Drug–Drug Interactions
Hepatic Drug Excretion: Influencing Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

